Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial of RRx-001 in Combination With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors

NCT04525014 is registered in ClinicalTrials.gov with EpicentRx, Inc. as lead sponsor.

NCT NCT04525014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04525014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial of RRx-001 in Combination With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
Lead sponsor
EpicentRx, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
January 26, 2023
Completion date
July 29, 2024
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumor, pediatric, brain tumor, recurrent, central nervous system neoplasms, unspecified childhood solid tumor, protocol specific